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ABSTRACT
Introduction: This case study aims to evaluate
outcomes following fluocinolone acetonide
[FAc 0.2 lg/day; ILUVIEN (Alimera Sciences
Limited, Aldershot, UK)] implant in a patient
with diabetic macular edema (DME) not
responding to laser photocoagulation or anti-
vascular endothelial growth factor (anti-VEGF)
therapy and to compare FAc implant with anti-
VEGF therapy in the fellow eye.
Case Report: The author presents here a patient
with DME for around 20 years in both eyes, who
had undergone pan-retinal and focal
photocoagulation, and anti-VEGF therapy in
both eyes without resolution of DME. FAc
implant in the left, and subsequently in the
right eye, provided substantial improvements in
edema and visual acuity.
Conclusion: In the current case, a benefit was
demonstrated in the FAc implant-treated left
eye at a time when the right eye was not
responding to anti-VEGF injections. If a patient
does not respond well to an anti-VEGF (i.e. first-
line therapy) in one eye, the treating physician
should consider switching the patient to a
corticosteroid implant (such as FAc implant)
in the fellow eye.
Keywords: Diabetic macular edema;
Fluocinolone acetonide; ILUVIEN; Ocular
coherence tomography; Visual acuity
INTRODUCTION
As a chronic, enduring condition, diabetic
macular edema (DME) has a significant burden
of low vision and blindness [1], is difficult to
manage, and therapeutic agents providing
sustained benefit are needed [2]. While DME
was once solely treated with laser therapy, a
large number of patients continued to lose
vision, despite treatment [3, 4]. Although anti-
vascular endothelial growth factor (anti-VEGF)
therapy has become the preferred treatment for
the management of DME, it is not effective in all
patients, as demonstrated in the RIDE
(ClinicalTrials.gov NCT00473382) and RISE
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(ClinicalTrials.gov NCT00473330) clinical trials,
where between 58% and 70% of patients gained
a best corrected visual acuity (BCVA) in Early
Treatment Diabetic Retinopathy Study (EDTRS)
letter score of C10 suggesting approximately
one-third of patients were insufficiently
responsive to anti-VEGF therapy [5].
Intravitreal steroids, particularly in sustained-
release implants, can offer a different DME
therapeutic strategy, by providing localized
delivery of the corticosteroid to maximize its
anti-inflammatory, angiostatic and anti-
permeability effects, as well as minimize risks of
systemic toxicity [3]. Fluocinolone acetonide
[0.2 lg/day FAc implant; ILUVIEN (Alimera
Sciences Limited, Aldershot, UK)] is a
nonbiodegradable intravitreal corticosteroid
implant that is delivered using a 25-gauge
injector [6, 7]. One implant releases sustained,
low-dose FAc (0.2 lg/day) for up to 3 years [8].
Currently, no direct comparative data exist
for anti-VEGF versus FAc implant therapy in
DME unresponsive to other therapies. Here, the
authors describe a patient case that provides
both direct comparison between anti-VEGF and
FAc implant in the fellow eye, and also insight
into the relative efficacy of FAc implant over
more than 1 year in DME not responding to
anti-VEGF therapy. This case has been reported
previously, but follow-up was limited to
12 weeks in one eye, without comparison to
the anti-VEGF-treated fellow eye [9].
CASE REPORT
This case is from a 30-year-old patient with type-
I diabetes who was diagnosed with DME around
20 years ago. The patient’s glycated hemoglobin
(HbA1c) was 9.5% and he was receiving insulin
therapy. The patient had previously undergone
pan-retinal and focal photocoagulation in both
eyes. Anti-VEGF therapy had also been
administered to both eyes prior to FAc implant,
with the right and left eye receiving 15 and 12
intravitreal ranibizumab injections, respectively,
since 2011; injections were administered
monthly wherever possible, although treatment
interruptions did occur due to reimbursement
issues and challenging patient compliance. This
report was carried out following informed
consent from the patient.
Treatment of the Left Eye
The patient received an FAc implant on August
16, 2013, at which time central macular
thickness (CMT) was 642 lm. Following FAc
implant, CMT decreased rapidly and markedly
(-364 lm at month 1) decreasing to 278 lm at
its minimum; the edema resolved quickly
following FAc implant, despite epiretinal
membrane formation (Fig. 1a). CMT remained
below 330 lm up to month 3 and then
increased slightly, measuring 442 lm at month
9 and 372 lm at month 13, still remaining more
than 250 lm below baseline CMT (Figs. 1, 2).
Best corrected visual acuity also increased
rapidly following FAc implant in the left eye
(Fig. 3; Table 1) improving from 0.3 at baseline
to 0.5 after 1 month. This change was sustained
through to month 9, although at month 13
BCVA decreased slightly to 0.4 as a result of
cataract formation, which was confirmed by
the return of BCVA to 0.5 1 day after
phacoemulsification. The macula at this point
still remained dry (see Fig. 1f).
Treatment of the Right Eye
The right eye was treated with a further three
injections of ranibizumab before an FAc
implant was injected (Table 1), a total of
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18 anti-VEGF injections. CMT was 654 lm prior
to ranibizumab injections, which decreased
thickness to 473 lm. However, 1 month after
FAc implant, CMT decreased from 473 to
263 lm (-210 lm) increasing slightly to
334 lm after 6 months (Table 1; Figs. 3, 4).
In the 7 months prior to FAc implant, BCVA
remained B0.5 in the right eye (Table 1). At 1
and 6 months after FAc implant, BCVA had
increased to 0.6 and 0.7, respectively.
Adverse Events
An increase in intraocular pressure (IOP) was
seen in the left eye of the current patient, rising
from 20 mmHg at month 3 to 32 mmHg, at
month 7. This change was managed with 10 mg
brinzolamide/5 mg timolol eye drops which
reduced IOP to 16 mmHg. At 13 months, left
and right eye IOP (6 months after FAc implant
had been administered) was 21 and 18 mmHg,
respectively.
No further adverse events have been
reported to date, at the time this case study
was accepted for publication (January 19, 2015).
DISCUSSION
FAc implant 0.2 lg/day is a second-line therapy
indicated for the treatment of vision
impairment associated with chronic diabetic
macular edema, considered insufficiently
responsive to available therapies [8, 10]. In the
present case, the patient had not responded
Fig. 1 Changes in macular thickness in the left eye before
and after ﬂuocinolone acetonide (FAc) implant. Optical
coherence tomography (OCT) scans of left eye diabetic
maculopathy in a patient with diabetic macular edema
(DME); a before treatment; b 1 month following FAc
implant; c 3 months after FAc implant; d 7 months post-
FAc implant injection; e 9 months following treatment;
and f 13 months after FAc implant injection
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sufficiently to prior treatments, which included
both laser and anti-VEGF therapy. This is
critically important in the chronic setting,
since intraretinal fluid accumulation resulting
in significant visual acuity reduction may be
reversible with continued anti-VEGF therapy,
but the prolonged edema can cause irreversible
damage resulting in permanent visual loss [1].
The rapid resolution in both edema and
BCVA after FAc implant seen in this case (as
early as 1 month post-implant) was also seen in
the FAME studies (ClinicalTrials.gov
NCT00344968) [2] where, in the chronic DME
group, central foveal thickness decreased by
week 6 and was sustained through to 36 months
[8]; however, subjects needed cataract surgery
more frequently following 0.2 lg/day FAc
implant than sham injection [2].
Two new insights relating to the indication
for FAc implant and its position in the
treatment algorithm are suggested by this
case. The first relates to the indication
statement that FAc implant is ‘for the
treatment of vision impairment associated
with chronic DME, considered insufficiently
responsive to available therapies’ [8]. The
current case provides a direct comparison
between the response to FAc implant, in the
left eye, and anti-VEGF, in the right eye
(Table 1). During the first 7 months following
FAc implant, the left eye showed rapid and
marked improvements in BCVA and CMT,
which were sustained. In contrast, BCVA did
not improve in the right eye, the change in
CMT was roughly half that of the left eye, and
the macula in the right eye remained swollen
and wet (Fig. 1), which could suggest that in
this chronic DME case, anti-VEGF was less
effective than FAc implant. This is further
supported by the subsequent response of the
right eye to FAc implant. A clear improvement
in BCVA and CMT was observed up to
6 months after FAc implant that achieved
similar absolute values to those in the left eye.
The second insight relates to the timing of
therapies. Prior to FAc implant being
administered, the patient had received
multiple anti-VEGF injections. Although the
left eye responded to FAc implant, anti-VEGF
treatment was continued for the right eye, with
Fig. 2 Changes in retinal thickness (lm) in the left eye
before and after ﬂuocinolone acetonide (FAc) implant.
Optical coherence tomography (OCT) retinal thickness
maps of left eye diabetic maculopathy in a patient with
diabetic macular edema (DME); a before treatment;
b 1 month following FAc implant; c 3 months after FAc
implant; d 7 months post-FAc implant injection;
e 9 months following treatment; and f 13 months after
FAc implant injection. Color indications: Green (displays
retinal thickness within normal limits), Yellow (retinal
thickness marginally outside normal limits), Red (retinal
thickness substantially outside normal limits)
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Fig. 3 Changes in best corrected visual acuity (BCVA)
and central macular thickness (CMT) before and after
ﬂuocinolone acetonide (FAc) implant. BCVA in a left eye
and b right eye, and CMT in c left eye and d right eye
following FAc implant. Red arrow indicates when the FAc
implant was ﬁrst inserted. ETDRS Early treatment Diabetic
Retinopathy study
Table 1 Changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) before and after
ﬂuocinolone acetonide (FAc) implant
Left eye Right eye
Time post-FAc implant BCVA CMT (lm) Time post-FAc implant BCVA CMT (lm)
Baseline 0.3 642.0 -7 months 0.5 639.0
?1 month 0.5 278.0 -6 months 0.4 568.0
?3 months 0.5 327.0 -4 months 0.1 654.0
?7 months 0.7 473.0 -1 month (baseline) 0.5a 473.0
?9 months 0.5 442.0 ?1 month 0.6 263.0
?13 months 0.4b 372.0 ?6 months 0.7 334.0
a Three further injections of ranibizumab (i.e., a total of 18 injections) had been administered prior to this time point
b At 13 months, BCVA in the left eye was 0.4, with the decrease being thought to relate to the formation of a cataract.
Phacoemulsiﬁcation was conducted at this stage and on the ﬁrst post-operative day, visual acuity had increased to 0.5. The
macula at this point was still dry
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three further injections of ranibizumab. In light
of the lack of response to anti-VEGF injections
and subsequent response to FAc implant in the
right eye, it may have been appropriate to
consider FAc implant sooner. An empirical
observation here is that the fellow eye could
be a useful guide to subsequent responses in the
contralateral eye. This of course needs to be
explored further and will hopefully be answered
through additional patient cases or studies.
In addition to the measurable clinical benefit,
it is vitally important to consider the patient’s
perspective. In the current case, the patient
worked as a window cleaner on high-rise
buildings, but was unable to continue working
prior to FAc implant. Following the implant,
which may have improved patient compliance as
a long-lasting (up to 3 years) consistent therapy,
he indicated he felt comfortable returning to
work and restarted his previous job. This reflects
Fig. 4 Changes in macular thickness (lm) in the right eye
before and after ﬂuocinolone acetonide (FAc) implant.
Optical coherence tomography (OCT) scans (left side) and
corresponding retinal thickness maps (right side) for right
eye diabetic maculopathy in a patient with diabetic macular
edema (DME); a before FAc implant but following
eighteen injections of ranibizumab; b 1 month following
FAc implant; c 6 months after FAc implant. Color
indications: Green (displays retinal thickness within normal
limits), Yellow (retinal thickness marginally outside normal
limits), Red (retinal thickness substantially outside normal
limits), Blue (shows reduction in macular thickness)
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an important, real-world functional benefit
resulting from the improvement in BCVA to 0.5,
or 20/40 in the left eye; an outcome also
important as it is the minimum requirement for
maintaining a driving license in Europe [11].
In this case, an initial challenge with
intraocular steroid was not provided as this is
not required in the European SmPC guidelines [8].
However, it should be noted that the United States
Food and Drug Administration (FDA) prescribing
information does stipulate that patients, ‘have
been previously treated with a course of
corticosteroids and did not have a clinically
significant rise in intraocular pressure’ [10].
CONCLUSION
This case report demonstrates the potential
effectiveness of ILUVIEN in a real-world
clinical setting, and suggests that FAc implant
or another corticosteroid should be considered
if the patient does not respond optimally to an
anti-VEGF and/or laser treatment. FAc implant
may provide additional treatment compliance
benefits as a result of the sustained low-dose
delivery of FAc (0.2 lg/day) for up to 3 years [2].
The current case is the first, that the authors are
aware of, to show: (a) a direct comparison
between the responses to FAc implant and
anti-VEGF injection; and, (b) that when a
patient is not responding optimally to anti-
VEGF therapy, FAc implant was effective and
provided similar effects to those achieved in the
contralateral eye previously treated with FAc
implant.
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